The Chinese herb Xiaoaiping protects against breast cancer chemotherapy-induced alopecia and other side effects: a randomized controlled trial

Fujie Yu*, Yuanmei Li*, Jiaqun Zou, Lisha Jiang, Chun Wang, Yi Tang, Bo Gao, Donglin Luo and Xiaojuan Jiang

Abstract

Objective: To investigate the effects of the Chinese herbal medicine Xiaoaiping to treat chemotherapy-induced side effects in breast cancer patients.

Methods: Ninety-three adult patients who attended our hospital and met the entry criteria from January 2016 to December 2017 were included. Patients were randomly divided into the control group (routine chemotherapy only) and the combined group (routine chemotherapy and Xiaoaiping). Demographic data and clinical variables were collected, and side effects including alopecia, nausea and vomiting, diarrhea, white blood cell (WBC) count, aspartate aminotransferase (AST) levels, and the quality of life were evaluated.

Results: Basic clinical characteristics were not different between the groups. There were significantly fewer patients with alopecia grade 3–4, but significantly more patients with alopecia grade 1–2, in the combined group compared with the control group. Disease-free time for alopecia was longer in the combined compared with the control group. Overall, the side effects were significantly more serious in the control compared with the combined group. Patients in the combined group had better quality of life than the control patients.

Conclusion: Xiaoaiping can improve alopecia, nausea and vomiting, and diarrhea symptoms, WBC count, AST levels, and the quality of life in breast cancer patients.

*Co-first authors.

Corresponding author:
Xiaojuan Jiang, Breast Thyroid Surgery, Army Military University Daping Hospital Institute of Field Surgery, No. 10 Changjiang Road, Daping, Chongqing 400042, China.
Email: xiaojuan87@tom.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Xiaoaiping, breast cancer, chemotherapy-induced side effects, alopecia, Marsdeniae tenacissimae, quality of life, Chinese herbal medicine

Date received: 13 November 2018; accepted: 18 March 2019

Introduction
Breast cancer is the most prevalent cancer and the leading cause of cancer-related death in women, accounting for 23% of all cancers and 14% of cancer-related deaths worldwide. Breast cancer is mostly treated with surgery and chemotherapy, which are usually used in combination. Although systemic chemotherapy is an important approach that is used in combination with surgery and radiation therapy to treat breast cancer, the side effects after chemotherapy are problematic, causing a huge burden for the patients. Among the side effects such as vomiting, diarrhea, and reduced leukocyte count, alopecia is another common and emotionally traumatic side effect of chemotherapy, especially for female patients. Patients with alopecia always have increased psychological distress and decreased body image and self-esteem. Studies also show that alopecia is one of the reasons that patients refuse potentially lifesaving chemotherapy. Reducing the degree of alopecia is a challenge, but it will help to improve the patients’ quality of life.

Several methods have attempted to reduce chemotherapy-induced alopecia, such as scalp tourniquets, pulsed electrostatic fields, topical treatments, and scalp cooling, and scalp cooling was reported to show good efficacy in reducing alopecia. However, these treatments do not reduce other side effects that are induced by chemotherapy and they can also increase alopecia.

Chinese herbal medicine is widely used in China. An increasing number of studies have shown that drugs used in combination with Chinese herbal medicine might demonstrate both good efficacy and safety in cancer treatment. However, to date, no study has focused on the use of Chinese herbal medicine treatments for chemotherapy-induced alopecia.

Xiaoaiping, a drug that is mainly composed of the Chinese herb Marsdeniae tenacissimae was approved by the Chinese State Food and Drug Administration (Z20063919). It has passed animal and human testing, and it has been used in clinics in China. It is widely used in cancer treatment in China. The present study aimed to investigate Xiaoaiping in the treatment of chemotherapy-induced alopecia and other side effects in breast cancer patients using a randomized controlled trial. This study may provide clinical evidence for the use of Marsdeniae tenacissimae to treat side effects of breast cancer chemotherapy and may provide new research targets for breast cancer research.

Methods and materials
Patients and treatment
In this prospective study, 93 adult patients who attended our hospital from January 2016 to December 2017 and met the study entry criteria were enrolled. All patients were diagnosed with breast cancer that was confirmed via histological analysis,
and all patients had undergone a radical mastectomy to treat this cancer. The following patients were excluded: patients with alopecia and related diseases before the study; patients who did not need chemotherapy after surgery; patients with brain metastases; patients with other serious cardiovascular, liver, or renal diseases; and patients who could not complete the chemotherapy cycles.

The chemotherapy strategy included six cycles of docetaxel (75 mg/m²) and Adriamycin (50 mg/m²) (both purchased from Qilu Pharmaceutical Co., Ltd., Jinan, China) that were administered every 21 days. All patients were randomly divided into two groups using a computer-generated program, as follows: 1) the control group (n=47) included patients who were only treated with routine chemotherapy; and 2) the combined group (n=46) included patients who were treated with routine chemotherapy and Xiaoaiping (300 mg/tablet, purchased from Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing, China, and approved by the Chinese State Food and Drug Administration, Z20063919) at a dose of 7.2 g/day (2.4 g per dose, three times daily) for 2 weeks during each chemotherapy cycle. Informed consent was obtained from all patients. The present study was approved by the ethics committee of the Army Military University Daping Hospital.

**Measurement and Data collection**

Demographic data and clinical variables such as age, TNM stage, and pathological type were collected. Chemotherapy-induced side effects were defined using the World Health Organization (WHO) criteria. Alopecia was defined as follows: grade 0, no change; grade 1, minimal hair loss; grade 2, moderate, patchy alopecia; and grade 3, complete and non-reversible alopecia. Nausea and vomiting were defined as follows: grade 0, no change; grade 1, mild nausea and vomiting; grade 2, temporary vomiting; grade 3, vomiting that needed treatment; and grade 4, uncontrollable vomiting. Diarrhea was defined as follows: grade 0, no diarrhea; grade 1, transient diarrhea less than 2 days; grade 2, diarrhea more than 2 days but tolerable; grade 3, tolerable diarrhea that needed treatment; and grade 4, bloody diarrhea. The lowest white blood cell (WBC) count and highest aspartate aminotransferase (AST) levels for each patient during chemotherapy were recorded and the grade was defined using the WHO criteria, as follows: for WBC, grade 0, \( \geq 4.0 \times 10^9/\text{L} \); grade 1, 3.0–3.9 \( \times 10^9/\text{L} \); grade 2, 2.0–2.9 \( \times 10^9/\text{L} \); grade 3, 1.0–1.9 \( \times 10^9/\text{L} \); and grade 4, \(< 1.0 \times 10^9/\text{L} \); and for AST, grade 0, \(< 1.25 \times 40 \text{ U/L} \); grade 1, 1.26–2.50 \( \times 40 \text{ U/L} \); grade 2, 2.6–5.0 \( \times 40 \text{ U/L} \); grade 3, 5.1–10.0 \( \times 40 \text{ U/L} \); and grade 4, \( >10.0 \times 40 \text{ U/L} \). Patients’ quality of life was evaluated using the Total Functional Assessment of Cancer Therapy – Breast (FACT-B) score (TQOL), which is calculated by adding the breast cancer-specific well-being scores (BWB), emotional well-being scores (EWB), functional well-being scores (FWB), physical well-being scores (PWB), and social and family wellbeing scores (SWB). The higher scores represented a better quality of life. The alopecia-free time was defined as the duration from the study beginning to the time when alopecia (grade 1–4) was first observed in patients.

**Statistical analysis**

The Chi-square test was used to compare the factors and rates. Comparison between two groups of continuous data was performed using the Student’s t-test. A Kaplan–Meier analysis was performed to measure the alopecia-free time. The measurement data were expressed as the mean ± standard deviation (SD). A P-value less
than 0.05 was considered to be statistically significant. All calculations were made using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Patients’ clinical characteristics**

As shown in Table 1, 93 patients were enrolled into this study, with 47 patients in the control group (mean age, 51.5 ± 8.6 years) and 46 patients in the combined group (mean age, 52.4 ± 10.5 years). Overall, 81 patients were diagnosed with TNM stage I–II and 12 patients were diagnosed with TNM stage II–IV cancer. Thirty-seven patients were diagnosed with Luminal-A type, 32 patients were diagnosed with Luminal-B type, and 24 patients were diagnosed with HER-2 overexpressed-type breast cancer. No significant differences were found among the basic clinical characteristics between the two groups.

**Efficacy of Xiaoaiping on alopecia**

The effect of Xiaoaiping on alopecia is shown in Table 2 and Figure 1. Overall, no patient showed a change in alopecia (i.e. an alopecia grade of 0). However, between the two groups, there were significantly fewer patients with alopecia grade 3–4 in the combined group compared with the control group (P < 0.05). Additionally, there were more patients with alopecia grade 1–2 in the combined group compared with the control group (P < 0.05). The Kaplan–Meier analysis also showed that patients in the combined group had a longer disease-free time from alopecia compared with patients in the control group (P < 0.05). These results suggest that Xiaoaiping treatment may improve the alopecia condition in breast cancer patients undergoing chemotherapy.

**Table 1. Patients’ basic clinical characteristics.**

|                      | Control group (n = 47) | Combined group (n = 46) |
|----------------------|------------------------|-------------------------|
| Age, year            | 51.5 ± 8.6             | 52.4 ± 10.5             |
| TNM stage, n (%)     |                        |                         |
| I–II                 | 40 (85.1)              | 41 (89.1)               |
| III–IV               | 7 (14.9)               | 5 (10.9)                |
| Pathological types, n (%) |                    |                         |
| Luminal-A            | 20 (42.6)              | 17 (37.0)               |
| Luminal-B            | 16 (34.0)              | 16 (34.8)               |
| HER-2 overexpressed  | 11 (23.4)              | 13 (28.3)               |

**Table 2. Comparison of alopecia between the two groups.**

| Alopecia grade, n (%) | Control group n = 47 | Combined group n = 46 | P value |
|-----------------------|-----------------------|------------------------|---------|
| Grade 0               | 0 (0)                 | 0 (0)                  | <0.001  |
| Grade 1               | 7                     | 16                     |         |
| Grade 2               | 24                    | 23                     |         |
| Grades 1 and 2        | 31 (66.0)             | 39 (84.8)*             |         |
| Grade 3               | 13                    | 7                      |         |
| Grade 4               | 3                     | 0                      |         |
| Grades 3 and 4        | 16 (34.0)             | 7 (15.2)*              |         |

*P < 0.05, compared with the control group.

**Figure 1.** Kaplan–Meier curve for alopecia-free time in the two groups of patients.
To further investigate the effects of Xiaoaiping, other side effects of nausea and vomiting, diarrhea, decreased WBC, and increased AST were evaluated. As shown in Table 3, overall, the effects were significantly more serious in the control group compared with the combined group (P < 0.05). These results suggest that Xiaoaiping may also reduce other side effects caused by chemotherapy.

### Table 3. Comparison of clinical outcomes between the two groups.

| Grade, n (%)       | Control group (n=47) | Combined group (n=46) | P value |
|--------------------|----------------------|-----------------------|---------|
| Nausea and vomiting|                      |                       |         |
| Grade 0            | 7 (14.9)             | 14 (30.4)             | <0.001  |
| Grade 1            | 10 (21.3)            | 16 (34.8)             |         |
| Grade 2            | 18 (38.3)            | 14 (30.4)             |         |
| Grade 3            | 11 (23.4)            | 2 (4.3)               |         |
| Grade 4            | 1 (2.1)              | 0 (0)                 |         |
| Diarrhea           |                      |                       |         |
| Grade 0            | 19 (40.4)            | 22 (47.8)             | 0.001   |
| Grade 1            | 3 (6.4)              | 13 (28.2)             |         |
| Grade 2            | 18 (38.3)            | 7 (15.2)              |         |
| Grade 3            | 6 (12.8)             | 3 (6.5)               |         |
| Grade 4            | 1 (2.1)              | 0 (0)                 |         |
| Decreased WBC count|                      |                       |         |
| Grade 0            | 4 (8.5)              | 8 (17.9)              | 0.001   |
| Grade 1            | 12 (25.5)            | 17 (36.9)             |         |
| Grade 2            | 16 (34.0)            | 15 (32.6)             |         |
| Grade 3            | 12 (25.5)            | 5 (10.8)              |         |
| Grade 4            | 3 (6.4)              | 1 (2.2)               |         |
| Increased AST level|                      |                       |         |
| Grade 0            | 33 (70.2)            | 44 (95.6)             | 0.003   |
| Grade 1            | 6 (12.8)             | 2 (4.3)               |         |
| Grade 2            | 8 (17.0)             | 1 (2.2)               |         |
| Grade 3            | 0                    | 0                     |         |
| Grade 4            | 0                    | 0                     |         |

BWB, cancer-specific well-being scores; EWB, emotional well-being scores; FWB, functional well-being scores; PWB, physical well-being scores; SWB, social and family wellbeing scores.

### Efficacy of Xiaoaiping on patients’ quality of life

We also analyzed the effects of Xiaoaiping on patients’ quality of life. The TQOL scores in the combined group were significantly higher compared with the control group (P < 0.05, Table 4), indicating a better quality of life for patients in the combined group compared with the control group. Additionally, all BWB, EWB, FWB, PWB, and SWB scores in the combined group were significantly higher compared with those in the control group (P < 0.05), suggesting that Xiaoaiping can enhance the quality of life in patients with breast cancer who are undergoing chemotherapy.

### Discussion

Among the side effects caused by chemotherapy, alopecia is an emotionally traumatic and common side effect that may worsen a patient’s depression and anxiety, as well as reduce their quality of life. This adds a huge burden to a patient’s life.19 It has been reported that scalp cooling can be used to treat chemotherapy-induced alopecia; however, it cannot protect against other side effects induced by chemotherapy. In this present study, we showed, for the first time, that Xiaoaiping, a drug that is mainly composed of the Chinese herb Marsdeniae tenacissimae, has the potential to protect breast cancer patients against chemotherapy-induced alopecia and other side effects.

Application of herbs in cancer treatment and chemotherapy-induced side effects have been reported in several studies. In a review, Zhang et al.20 showed that Chinese herbal medicine might improve symptoms of chemotherapy-induced nausea and vomiting as well as fatigue, and might improve the patients’ quality of life. Oh et al.21 conducted a systematic review and found that...
herbal medicine could be used to treat side effects of chemotherapy in breast cancer patients. In a recent study, Miranzadeh et al.\(^{22}\) demonstrated that adding the herb Achillea millefolium to mouthwash given to chemotherapy patients reduced chemotherapy-induced oral mucositis. Several studies on application of *Marsdeniae tenacissimae* in cancer treatment were previously reported. Zhu et al.\(^{23}\) showed that total aglycones from *Marsdeniae tenacissimae* could increase the antitumor efficacy of paclitaxel. Chen et al. found that *Marsdeniae tenacissimae* extracts could suppresses cell proliferation and promote apoptosis in human umbilical vein endothelial cells.\(^{24}\) Zhang et al.\(^{17}\) demonstrated that *Marsdeniae tenacissimae* could be used to treat advanced non-small cell lung cancer. In the present study, we found that Xiaoaiping, which is mainly composed of *Marsdeniae tenacissimae*, could significantly reduce the side effects induced by chemotherapy in breast cancer patients.

Xiaoaiping is a single-extract preparation of tongguan vine, which is mainly used to treat cancers such as liver cancer, stomach cancer, non-small cell lung cancer, colon cancer, and breast cancer,\(^{25}\) and it is also used to treat childhood asthma and chronic bronchitis in old age. Additionally, Xiaoaiping has anti-viral, anti-bacterial, analgesic, and detoxification functions.\(^{24}\)

Research on the anti-tumor pharmacological effects of Xiaoaiping has been conducted mainly on the following two aspects: 1) direct anti-tumor effects, such as inhibiting tumor cell proliferation, promoting differentiation, inducing apoptosis, and inhibiting tumor cell angiogenesis;\(^{26}\) and 2) its enhancing effect and role in reducing toxicity in combination with other anti-cancer drugs. Han et al.\(^{27}\) showed that the Xiaoaiping-induced angiogenesis was related to the expression of drug resistance-related proteins such as p13k and its downstream signaling molecules.

The present study also has some limitations. First, the sample size was small. Second, the underlying molecular mechanisms for Xiaoaiping remain unclear. Thus, further research is required to confirm our results.

In conclusion, we conducted a randomized controlled study to investigate the effects of the Chinese herbal medicine Xiaoaiping in the treatment of chemotherapy-induced side effects. The results showed that Xiaoaiping could improve alopecia, nausea and vomiting, diarrhea, WBC count, AST levels, and the quality of life in breast cancer patients who are undergoing chemotherapy. This study may provide clinical evidence for the use of *Marsdeniae tenacissimae* in the treatment of breast cancer and might provide new targets for breast cancer research.

**Acknowledgments**

This work is supported by Chongqing Science and Technology Huimin Plan (cstc2016kjhmpt1001-16).

**Table 4.** Comparison of patients’ quality of life using the TQOL score between the two groups.

| Scores        | Control group (n=47) | Combined group (n=46) | P value |
|---------------|----------------------|-----------------------|---------|
| TQOL          | BWB 23.2 ± 4.6       | 26.5 ± 5.7            | 0.001   |
|               | EWB 13.5 ± 4.4       | 16.9 ± 3.6            | 0.001   |
|               | FWB 10.9 ± 3.0       | 14.1 ± 3.0            | 0.001   |
|               | PWB 20.2 ± 4.3       | 23.4 ± 5.2            | 0.001   |
|               | SWB 13.3 ± 4.1       | 16.4 ± 4.1            | 0.001   |
| TQOL after treatment | 81.5 ± 17.9 | 97.3 ± 19.3 | 0.001 |

TQOL, Total Functional Assessment of Cancer Therapy – Breast (FACT-B) score; BWB, cancer-specific well-being scores; EWB, emotional well-being scores; FWB, functional well-being scores; PWB, physical well-being scores; SWB, social and family well-being scores.
Authors’ contributions
Fujie Yu and Yuanmei Li wrote the manuscript. Jiaqun Zou, Lisha Jiang, Chun Wang, and Yi Tang contributed to the discussion and Bo Gao, Donglin Luo, and Xiaojuan Jiang contributed to and commented on an earlier version of the manuscript.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Ethics approval
Ethics approval was obtained from the Ethics Committee of the Army Military University Daping Hospital Institute of Field Surgery.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Xiaojuan Jiang https://orcid.org/0000-0001-9424-7669

References
1. Seker MM, Yucel B, Seker A, et al. Treatment and prognosis of breast cancer in elderly: different from young patients? Eur Geriatric Med 2014; 5: 261–264.
2. Darby SC, Ewertz M, McCale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987–998.
3. Koyama H, Nishizawa Y, Wada T, et al. Intra-arterial infusion chemotherapy as an induction therapy in multidisciplinary treatment for locally advanced breast cancer. A long-term follow-up study. Cancer 2015; 56: 725–729.
4. Carlson RW, Anderson BO, Chopra R, et al. Treatment of breast cancer in countries with limited resources. Breast J 2015; 9: S67–S74.
5. Beusterien K, Grinspan J, Kuchuk I, et al. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 2014; 19: 127.
6. Lorusso D, Bria E, Costantini A, et al. Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care 2016; 26: 1–9.
7. Tomoo S, Jun-ichi T, Tositaka F, et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 2013; 43: 483–491.
8. Shiiba T, Kondo R, Harti S, et al. 1563 A topical botanical lotion improves recovery from chemotherapy alopecia and persistent hair issues in cancer survivors through local modulation of apoptosis and inflammation. Eur J Cancer 2015; 51: S225.
9. Chon SY, Champion RW, Geddes ER, et al. Chemotherapy-induced alopecia. J Am Acad Dermatol 2012; 67: e37–e47.
10. Maxwell MB. Scalp tourniquets for chemotherapy-induced alopecia. Am J Nurs 1980; 80: 900–903.
11. Maddin WS, Bell PW and James JH. The biological effects of a pulsed electrostatic field with specific reference to hair. Electrotrichogenesis. Int J Dermatol 2010; 29: 446–450.
12. Mitchell AJ and Douglass MC. Topical photof chemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12: 644–649.
13. Campenni GM, Munzone E, Bianco N, et al. F16Preventing chemotherapy-induced alopecia by scalp cooling: preliminary data from a study on the efficacy and safety of dignicare System in breast cancer patients. Ann Oncol 2016; 27: iv63–iv64.
14. Lemieux J, Maunsell E, Provencher L, et al. Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling. J Clin Oncol 2012; 30: 9138–9138.
15. Wang Q, Wang Q, Wang SF, et al. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Curr Oncol 2017; 24: e269.
16. Vch C, Wu X, Hui EP, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. *Sci Rep* 2015; 5: 18111.

17. Zhang H, Zhang J, Ding H, et al. Clinical value of Tongguanteng (Radix seu Herba Marsdeniae Tenacissimae) extract combined with chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis. *J Trad Chinese Med* 2016; 36(3): 261–270.

18. Yan B, Yang LM, Hao LP, et al. Determinants of quality of life for breast cancer patients in Shanghai, China. *Plos One* 2016; 11: e0153714.

19. Rossi A, Fortuna MC, Caro G, et al. Chemotherapy-induced alopecia management: clinical experience and practical advice. *J Cosme Derm* 2017; 16: 1–4.

20. Zhang M, Liu X, Li J, et al. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. *Cochrane Database Syst Rev* 2007; 18: CD004921.

21. Oh J, Kim EH, Kim JH, et al. Herbal medicine to treat the side effects of chemotherapy in breast cancer patients: systematic review. *Eur J Integr Med* 2016; 8: 51–56.

22. Miranzadeh S, Adib-Hajbaghery M, Soleymanpoor L, et al. Effect of adding the herb Achillea millefolium on mouthwash on chemotherapy induced oral mucositis in cancer patients: a double-blind randomized controlled trial. *Eur J Oncol Nurs* 2015; 19: 207–213.

23. Zhu RJ, Shen XL, Dai LL, et al. Total aglycones from Marsdenia tenacissima increases antitumor efficacy of paclitaxel in nude mice. *Molecules* 2014; 19: 13965–13975.

24. Chen BY, Dong C, Lyu JX, et al. Marsdeniae tenacissimae extract (MTE) suppresses cell proliferation by attenuating VEGF/VEGFR2 interactions and promotes apoptosis through regulating PKC pathway in human umbilical vein endothelial cells. *Chin J Nat Med* 2016; 14: 922–930.

25. Wang MJ, Du DY, Fan W, et al. [Effects and mechanisms of Xiao-Ai-Ping injection on angiogenesis]. *Yao Xue Bao* 2016; 51: 309–315.

26. Dai XB, Ji YH, Jiang PJ, et al. Marsdenia tenacissima extract suppresses tumor growth and angiogenesis in A20 mouse lymphoma. *Oncol Lett* 2017; 13: 2897–2902.

27. Han SY, Zheng WX, He XR, et al. Xiaoaiping injection combined with gefitinib inhibits resistant non-small cell lung cancer xenografts H460 and H1975. *Chin J Pharmacol Toxicol* 2016; 30: 44–52.